Global Polycystic Kidney Disease Drugs Market 2019-2023
SKU ID : TNV-14416351 | Publishing Date : 17-Jun-2019 | No. of pages : 125
Detailed TOC of Global Polycystic Kidney Disease Drugs Market 2019-2023
PART 01: EXECUTIVE SUMMARYPART 02: SCOPE OF THE REPORT
2.1 Preface
2.2 Preface
2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
Market ecosystem
Market characteristics
Market segmentation analysis
PART 04: MARKET SIZING
Market definition
Market sizing 2018
Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
Bargaining power of buyers
Bargaining power of suppliers
Threat of new entrants
Threat of substitutes
Threat of rivalry
Market condition
PART 06: PIPELINE ANALYSIS
PART 07: MARKET SEGMENTATION BY TYPE
Market segmentation by type
Comparison by type
ADPKD - Market size and forecast 2018-2023
ARPKD - Market size and forecast 2018-2023
Market opportunity by type
PART 08: CUSTOMER LANDSCAPE
PART 09: GEOGRAPHIC LANDSCAPE
Geographic segmentation
Geographic comparison
North America - Market size and forecast 2018-2023
Europe - Market size and forecast 2018-2023
Asia - Market size and forecast 2018-2023
ROW - Market size and forecast 2018-2023
Key leading countries
Market opportunity
PART 10: DECISION FRAMEWORK
PART 11: DRIVERS AND CHALLENGES
Market drivers
Market challenges
PART 12: MARKET TRENDS
Increasing research funding
Favorable reimbursement policies
Growing awareness about kidney diseases
PART 13: VENDOR LANDSCAPE
Overview
Landscape disruption
Competitive scenario
PART 14: VENDOR ANALYSIS
Vendors covered
Vendor classification
Market positioning of vendors
Johnson & Johnson Services Inc.
Merck & Co., Inc.
Otsuka Holdings Co. Ltd.
Reata Pharmaceuticals Inc.
Sanofi
PART 15: APPENDIX
Research methodology
List of abbreviations
Definition of market positioning of vendors
PART 16: EXPLORE TECHNAVIO
Exhibit 01: Global pharmaceuticals market
Exhibit 02: Segments of global pharmaceuticals market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Market definition - Inclusions and exclusions checklist
Exhibit 06: Market size 2018
Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 09: Five forces analysis 2018
Exhibit 10: Five forces analysis 2023
Exhibit 11: Bargaining power of buyers
Exhibit 12: Bargaining power of suppliers
Exhibit 13: Threat of new entrants
Exhibit 14: Threat of substitutes
Exhibit 15: Threat of rivalry
Exhibit 16: Market condition - Five forces 2018
Exhibit 17: Some of the clinical stage drugs for polycystic kidney disease
Exhibit 18: Type - Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: ADPKD - Market size and forecast 2018-2023 ($ millions)
Exhibit 21: ADPKD - Year-over-year growth 2019-2023 (%)
Exhibit 22: ARPKD - Market size and forecast 2018-2023 ($ millions)
Exhibit 23: ARPKD - Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America - Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America - Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe - Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe - Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia - Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW - Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW - Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 42: Prevalence of chronic kidney diseases per 100 people
Exhibit 43: Impact of drivers and challenges
Exhibit 44: Vendor landscape
Exhibit 45: Landscape disruption
Exhibit 46: Vendors covered
Exhibit 47: Vendor classification
Exhibit 48: Market positioning of vendors
Exhibit 49: Johnson & Johnson Services Inc. - Vendor overview
Exhibit 50: Johnson & Johnson Services Inc. - Business segments
Exhibit 51: Johnson & Johnson Services Inc. - Organizational developments
Exhibit 52: Johnson & Johnson Services Inc. - Geographic focus
Exhibit 53: Johnson & Johnson Services Inc. - Segment focus
Exhibit 54: Johnson & Johnson Services Inc. - Key offerings
Exhibit 55: Johnson & Johnson Services Inc. - Key customers
Exhibit 56: Merck & Co. Inc. - Vendor overview
Exhibit 57: Merck & Co. Inc. - Business segments
Exhibit 58: Merck & Co. Inc. - Organizational developments
Exhibit 59: Merck & Co. Inc. - Geographic focus
Exhibit 60: Merck & Co. Inc. - Segment focus
Exhibit 61: Merck & Co. Inc. - Key offerings
Exhibit 62: Merck & Co. Inc. - Key customers
Exhibit 63: Otsuka Holdings Co. Ltd. - Vendor overview
Exhibit 64: Otsuka Holdings Co. Ltd. - Business segments
Exhibit 65: Otsuka Holdings Co. Ltd. - Organizational developments
Exhibit 66: Otsuka Holdings Co. Ltd. - Geographic focus
Exhibit 67: Otsuka Holdings Co. Ltd. - Segment focus
Exhibit 68: Otsuka Holdings Co. Ltd. - Key offerings
Exhibit 69: Otsuka Holdings Co. Ltd. - Key customers
Exhibit 70: Reata Pharmaceuticals Inc. - Vendor overview
Exhibit 71: Reata Pharmaceuticals Inc. - Organizational developments
Exhibit 72: Reata Pharmaceuticals Inc. - Key offerings
Exhibit 73: Reata Pharmaceuticals Inc. - Key customers
Exhibit 74: Sanofi - Vendor overview
Exhibit 75: Sanofi - Business segments
Exhibit 76: Sanofi - Organizational developments
Exhibit 77: Sanofi - Geographic focus
Exhibit 78: Sanofi - Segment focus
Exhibit 79: Sanofi - Key offerings
Exhibit 80: Sanofi - Key customers
Exhibit 81: Validation techniques employed for market sizing
Exhibit 82: Definition of market positioning of vendors
Keyplayers in Global Polycystic Kidney Disease Drugs Market 2019-2023
Johnson & Johnson Services Inc.Merck & Co., Inc.
Otsuka Holdings Co. Ltd.
Reata Pharmaceuticals Inc.
Sanofi.